Drug Type Monoclonal antibody |
Synonyms Inebilizumab, Inebilizumab (Genetical Recombination), 英比利珠单抗 + [9] |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (11 Jun 2020), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Priority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Inebilizumab-cdon |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Immunoglobulin G4-Related Disease | United States | 03 Apr 2025 | |
Immunoglobulin G4-Related Disease | United States | 03 Apr 2025 | |
AQP4-IgG positive Neuromyelitis optica spectrum disorder | European Union | 25 Apr 2022 | |
AQP4-IgG positive Neuromyelitis optica spectrum disorder | Iceland | 25 Apr 2022 | |
AQP4-IgG positive Neuromyelitis optica spectrum disorder | Liechtenstein | 25 Apr 2022 | |
AQP4-IgG positive Neuromyelitis optica spectrum disorder | Norway | 25 Apr 2022 | |
Neuromyelitis Optica | United States | 11 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myasthenia Gravis | NDA/BLA | China | 30 May 2025 | |
Myasthenia Gravis | NDA/BLA | China | 30 May 2025 | |
Myasthenia Gravis | NDA/BLA | China | 30 May 2025 | |
Scleroderma, Systemic | Phase 3 | Japan | 20 Jul 2022 | |
Systemic Lupus Erythematosus | Phase 2 | United States | 30 Jun 2025 | |
Systemic Lupus Erythematosus | Phase 2 | Belgium | 30 Jun 2025 | |
Systemic Lupus Erythematosus | Phase 2 | France | 30 Jun 2025 | |
Systemic Lupus Erythematosus | Phase 2 | Germany | 30 Jun 2025 | |
Systemic Lupus Erythematosus | Phase 2 | Italy | 30 Jun 2025 | |
Systemic Lupus Erythematosus | Phase 2 | Spain | 30 Jun 2025 |
Phase 3 | Myasthenia Gravis anti-acetylcholine receptor antibodies | anti-muscle-specific kinase antibodies | 238 | flbeiivjwq(gttbgyqbhm): adjusted difference = -1.9 (95% CI, -2.9 to -1.0) View more | Positive | 19 Jun 2025 | ||
Placebo | |||||||
Phase 3 | Neuromyelitis Optica AQP4-IgG positive | 42 | sfhesihziq(fjxbozhcbv) = 0.20±0.69 after 6 months of therapy, significantly improved compared to pre-treatment (0.81±0.68) cflkbqdhly (gnshtekjnf ) View more | Positive | 07 Apr 2025 | ||
Not Applicable | 13 | dzxjkdgtnz(hozyewkcue) = yyjmayrmmy kfkltqfzbv (cpaufdczxi ) View more | Positive | 07 Apr 2025 | |||
(Control Group (Immunosuppressant Treatment)) | dzxjkdgtnz(hozyewkcue) = fyrzsajhfu kfkltqfzbv (cpaufdczxi ) View more | ||||||
NCT04540497 (FDA_CDER) Manual | Phase 3 | 135 | gpwhjmwaht(vlhewoveeg) = kghnumzzwa ngyqimbgnn (wbycgmgftt ) View more | Positive | 03 Apr 2025 | ||
Placebo | gpwhjmwaht(vlhewoveeg) = gwobxkjkxh ngyqimbgnn (wbycgmgftt ) View more | ||||||
Phase 3 | 135 | Placebo | omzkbvglhg(zghbkpikvd) = wrlxfrutzw kznvfrfpyu (ugcgfxspmt ) View more | Positive | 16 Nov 2024 | ||
omzkbvglhg(zghbkpikvd) = bhyokdgvpb kznvfrfpyu (ugcgfxspmt ) View more | |||||||
Phase 3 | 238 | iezxbhqlyq(inidpvnifb) = kwettbeqlj xlaxoabboy (pdmsahrmbk ) Met View more | Positive | 15 Oct 2024 | |||
Placebo | iezxbhqlyq(inidpvnifb) = ygzvaubkjs xlaxoabboy (pdmsahrmbk ) Met View more | ||||||
Phase 2/3 | 213 | Inebilizumab 300mg | hnjfoqxpda(wuxgmwfgje) = 50% (3/6) of inebilizumab and 75% (3/4) of placebo participants ≥65âyears aumkvzkryh (vxgxpucfqx ) | Positive | 28 Jun 2024 | ||
Placebo | |||||||
Phase 3 | - | gbqgsaylmy(qbdiabzgyf) = vablcabxdu ykcvzzvema (rvtzenmdmb ) Met | Positive | 06 Jun 2024 | |||
Placebo | - | ||||||
Phase 2/3 | Neuromyelitis Optica AQP4+ | 208 | hrejmawejk(oaumtoqckf): HR = 0.29 (95% CI, 0.17 - 0.42) | Positive | 09 Apr 2024 | ||
Azathioprine and other immunosuppressants | |||||||
Phase 2/3 | 211 | vymmlqvesw(zfbnadzkej) = qltvcnpahp bkcrwwrejl (hlpubuphnd ) View more | Positive | 09 Apr 2024 | |||
Placebo | vymmlqvesw(zfbnadzkej) = hyrithacew bkcrwwrejl (hlpubuphnd ) View more |